Alto Neuroscience, Inc. (ANRO) Stock Forecast & Price Target

Compare

550 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ANRO Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Alto

Neuroscience, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ANRO Stock 12 Month Forecast

Average Price Target

$35.67

▲(132.81% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Alto Neuroscience, Inc. in the last 3 months. The average price target is $35.67 with a high forecast of $50.00 and a low forecast of $25.00. The average price target represents a 132.81% change from the last price of $15.32.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","51":"$51","13.5":"$13.5","38.5":"$38.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,13.5,26,38.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.8,20.276923076923076,22.753846153846155,25.230769230769234,27.70769230769231,30.184615384615384,32.66153846153846,35.13846153846154,37.61538461538461,40.0923076923077,42.56923076923077,45.04615384615384,47.52307692307693,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.8,19.174358974358974,20.54871794871795,21.923076923076923,23.297435897435896,24.671794871794873,26.046153846153846,27.42051282051282,28.794871794871796,30.16923076923077,31.54358974358974,32.91794871794872,34.29230769230769,{"y":35.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.8,18.353846153846156,18.907692307692308,19.461538461538463,20.015384615384615,20.56923076923077,21.123076923076923,21.676923076923078,22.23076923076923,22.784615384615385,23.338461538461537,23.892307692307693,24.446153846153848,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.23,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.29,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$35.67

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$50

Buy

226.37%

Upside

Reiterated

01/21/26

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (NYSE: ANRO), Context Therapeutics (NASDAQ: CNTX) and Connect Biopharma Holdings (NASDAQ: CNTB)

Keay Nakae

Chardan Capital

$30

Buy

95.82%

Upside

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (NASDAQ: STOK), Fate Therapeutics (NASDAQ: FATE) and Alto Neuroscience, Inc. (NYSE: ANRO)

Thomas Shrader

BTIG

$27

Buy

76.24%

Upside

Reiterated

12/02/25

BTIG Keeps Their Buy Rating on Alto Neuroscience, Inc. (ANRO)

Andrew Tsai

Jefferies

$25

Buy

63.19%

Upside

Reiterated

11/18/25

Alto Neuroscience, Inc. (ANRO) Receives a Buy from Jefferies

Paul Matteis

Stifel Nicolaus

$33

Buy

115.40%

Upside

Reiterated

11/14/25

Stifel Nicolaus Keeps Their Buy Rating on Alto Neuroscience, Inc. (ANRO)

Ritu Baral

TD Cowen

Buy

―

Reiterated

11/13/25

Promising Future for Alto Neuroscience: Buy Rating Backed by Strong Financials and Innovative Treatment Prospects

Myles Minter

William Blair

Buy

―

Reiterated

11/12/25

Promising Future for Alto Neuroscience: Buy Rating Backed by Strong Financials and Clinical Advancements

Justin Walsh

JonesTrading

$13→$49

Buy

219.84%

Upside

Reiterated

11/12/25

Alto Neuroscience's ALTO-207: A Promising Candidate for Treatment-Resistant Depression with Significant Financial Projections

Brian Skorney

Robert W. Baird

$10→$16

Buy

4.44%

Upside

Reiterated

10/20/25

Alto Neuroscience price target raised to $16 from $10 at BairdAlto Neuroscience price target raised to $16 from $10 at Baird

Laura Chico

Wedbush

Hold

-73.89%

Downside

Reiterated

06/27/25

Wedbush Remains a Hold on Alto Neuroscience, Inc. (ANRO)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$50

Buy

226.37%

Upside

Reiterated

01/21/26

Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (NYSE: ANRO), Context Therapeutics (NASDAQ: CNTX) and Connect Biopharma Holdings (NASDAQ: CNTB)

Keay Nakae

Chardan Capital

$30

Buy

95.82%

Upside

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (NASDAQ: STOK), Fate Therapeutics (NASDAQ: FATE) and Alto Neuroscience, Inc. (NYSE: ANRO)

Thomas Shrader

BTIG

$27

Buy

76.24%

Upside

Reiterated

12/02/25

BTIG Keeps Their Buy Rating on Alto Neuroscience, Inc. (ANRO)

Andrew Tsai

Jefferies

$25

Buy

63.19%

Upside

Reiterated

11/18/25

Alto Neuroscience, Inc. (ANRO) Receives a Buy from Jefferies

Paul Matteis

Stifel Nicolaus

$33

Buy

115.40%

Upside

Reiterated

11/14/25

Stifel Nicolaus Keeps Their Buy Rating on Alto Neuroscience, Inc. (ANRO)

Ritu Baral

TD Cowen

Buy

―

Reiterated

11/13/25

Promising Future for Alto Neuroscience: Buy Rating Backed by Strong Financials and Innovative Treatment Prospects

Myles Minter

William Blair

Buy

―

Reiterated

11/12/25

Promising Future for Alto Neuroscience: Buy Rating Backed by Strong Financials and Clinical Advancements

Justin Walsh

JonesTrading

$13→$49

Buy

219.84%

Upside

Reiterated

11/12/25

Alto Neuroscience's ALTO-207: A Promising Candidate for Treatment-Resistant Depression with Significant Financial Projections

Brian Skorney

Robert W. Baird

$10→$16

Buy

4.44%

Upside

Reiterated

10/20/25

Alto Neuroscience price target raised to $16 from $10 at BairdAlto Neuroscience price target raised to $16 from $10 at Baird

Laura Chico

Wedbush

Hold

-73.89%

Downside

Reiterated

06/27/25

Wedbush Remains a Hold on Alto Neuroscience, Inc. (ANRO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alto Neuroscience, Inc.

3 Months

xxx

Success Rate

7/7 ratings generated profit

Average Return

+117.61%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +117.61% per trade.

1 Year

Justin WalshJonesTrading

Success Rate

10/10 ratings generated profit

Average Return

+406.54%

reiterated a buy rating 3 months ago

Copying Justin Walsh's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +406.54% per trade.

2 Years

xxx

Success Rate

10/10 ratings generated profit

Average Return

+406.11%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +406.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ANRO Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ANRO has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ANRO average Analyst price target in the past 3 months is 35.67.

Each month's total comprises the sum of three months' worth of ratings.

ANRO Financial Forecast

ANRO Earnings Forecast

The previous quarter’s earnings for ANRO were -$0.52.

No data currently available

ANRO Sales Forecast

The previous quarter’s earnings for ANRO were $0.00.

ANRO Stock Forecast FAQ

What is ANRO’s average 12-month price target, according to analysts?

Based on analyst ratings, Alto Neuroscience, Inc.’s 12-month average price target is 35.67.

What is ANRO’s upside potential, based on the analysts’ average price target?

Alto Neuroscience, Inc. has 132.81% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ANRO a Buy, Sell or Hold?

Alto Neuroscience, Inc. has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Alto Neuroscience, Inc.’s price target?

The average price target for Alto Neuroscience, Inc. is 35.67. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $25.00. The average price target represents 132.81% Increase from the current price of $15.32.

What do analysts say about Alto Neuroscience, Inc.?

Alto Neuroscience, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of ANRO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Alto Neuroscience, Inc. (ANRO) Stock Forecast & Price Target

ANRO Analyst Ratings

ANRO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alto Neuroscience, Inc.

ANRO Analyst Recommendation Trends

ANRO Financial Forecast

ANRO Earnings Forecast

ANRO Sales Forecast

ANRO Stock Forecast FAQ

Detailed List of Analyst Forecasts